Latest Breaking News On - Geron corporation - Page 1 : comparemela.com

Geron Co (NASDAQ:GERN) EVP Sells $1,332,977 00 in Stock

Geron Co. (NASDAQ:GERN – Get Free Report) EVP Faye Feller sold 287,900 shares of Geron stock in a transaction on Monday, June 10th. The shares were sold at an average price of $4.63, for a total value of $1,332,977.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is […]

United statesRobertw bairdFaye fellerStifel nicolausGeron coPathstone family officeHermes incGoldman sachs groupCrewe advisorsGeron company profileSecurities exchange commissionGeron corporationKingsview wealth managementGet free reportExchange commissionTrading down

Geron Drug Lands a First-in-Class FDA Approval in Type of Blood Cancer

Geron Drug Lands a First-in-Class FDA Approval in Type of Blood Cancer
medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.

United statesBristol myers squibbEuropean medicines agencyAmerican cancer societyGeron corporationCalifornia based geronEuropean medicines

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Approval across ESA ineligible and ESA relapsed/refractory patients with LR-MDS with transfusion-dependent anemia, regardless of ring sideroblast status Durable and sustained red blood cell.

Johna scarlettDrug administrationExchange commissionGeron corporation nasdaqMalignant hematology departmentMoffitt cancer centerPatient support programGeron corporationChief executiveRami komrokjiVice chairConference callEastern timePrescribing informationMedication guidePrivate securities litigation reform act

Geron Announces FDA Approval of RYTELO (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

07.06.2024 - Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO (imetelstat) for the . Seite 1

Johna scarlettGeron corporation nasdaqDrug administrationGeron corporationChief executive

Geron (NASDAQ:GERN) Stock Price Down 4 9%

Shares of Geron Co. (NASDAQ:GERN – Get Free Report) were down 4.9% during mid-day trading on Tuesday . The stock traded as low as $3.31 and last traded at $3.31. Approximately 4,843,223 shares changed hands during mid-day trading, a decline of 54% from the average daily volume of 10,500,104 shares. The stock had previously closed […]

Robertw bairdCrewe advisorsPathstone family officeNeedham companyGeron corporationPeaks wealth advisorsGeron coGoldman sachs groupHermes incKingsview wealth managementGet free reportFamily officeWealth managementTwin peaks wealth advisorsGeron daily